Proceedings of the National Academy of Sciences, Volume 123, Issue 13, March 2026. SignificanceCD47, a key innate immune checkpoint, limits phagocytosis by myeloid cells and enables cancer immune evasion, but anti-CD47 therapies show poor efficacy in glioblastoma (GBM). Here, we uncover a critical cell-intrinsic role for CD47 in GBM, ...
PNAS published a clinical update in Research Highlights on 23 Mar 2026.
The item focuses on CD47 stabilizes ROBO2 to regulate glioblastoma progression by preventing ITCH-mediated ubiquitination.
Review the original article for the full source wording and details.